Reunion is a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience to develop innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions that serve as safe, fast-acting, short duration therapies for underserved mental health disorders, beginning with postpartum depression (PPD). We envision a day when depression isn’t just a disorder that can be managed, but instead is curable. We relentlessly pursue the development of safer therapeutics that provide durable antidepressive effects for the millions of people whose needs are not met by the current standard of care.
RECENT NEWS AND MEDIA COVERAGE
November 18, 2024: How this psychedelic drug company went private and raised a $103M Series A
October 9, 2024: Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders
September 10, 2024: Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer
Leading with Bold Science
Our approach builds upon the decades of psychedelic research that reveals promising results across various mental health conditions. Our lead clinical-stage drug candidate, RE104, is a potential best-in-class, short duration, patented prodrug of 4-OH-DiPT, a psilocybin-like compound. RE104 targets the serotonin 2A receptor (5HT2AR), which is the recognized target for the antidepressant effects of psychedelic compounds.
Experience, Meet Innovation
Reunion’s team consists of industry entrepreneurs and scientific leaders with deep experience in every aspect of neuroscience pharmaceutical drug development. We’re blazing the path to create a transformative new generation of therapeutics to create a world where mental and emotional wellbeing is the baseline.
